Abstract
The development and implementation of CAR-T cells warrant ethical vigilance. This attention concerns both the conditions for evaluating these therapies in the context of clinical studies, the acceptable risks in the preference given to innovation regarding other reference therapies, the ability to develop manufacturing sectors in a public framework continuing the decisive contribution of academic research to these innovative concepts, also the negotiation of the “fair price” of treatments when drug companies offer prices considered excessive.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
